Breaking News

Cyprotex Expands Toxicology Capabilities

Adds 3D tissue and advanced mitochondrial toxicity analysis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cyprotex PLC has expanded its toxicology capabilities to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis. These capabilities follow the purchase of new instruments including a Thermo Scientific ArrayScan XTI high content screening (HCS) platform and a Seahorse XFe extracellular flux analyzer. The new technologies add greater specialization in toxicology and expanded pharmacological efficacy research capabilities.     Regulatory authorities have approved 3D sk...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters